Press Release
Category Added in a WPeMatico Campaign
-
ACL Digital Joins SAP® PartnerEdge® Program to Help Clients Advance Business Transformation and Accelerate Value
BENGALURU, India, Dec. 16, 2024 /PRNewswire/ — ACL Digital, an ALTEN group company and a global leader in design-led digital…
Read More » -
Spray Pyrolysis Market worth $234.2 million by 2029 – Exclusive Report by MarketsandMarkets™
DELRAY BEACH, Fla., Dec. 16, 2024 /PRNewswire/ — The report “Spray Pyrolysis Market by Device Type (Ultrasonic Spray Pyrolysis System, High-Throughput Spray…
Read More » -
Trimble and GroundProbe Collaborate to Offer Complete Monitoring Portfolio for Geotechnical and Geospatial Mining Professionals
Integrated approach means less hassle and more support for complete slope stability monitoring solutions WESTMINSTER, Colo. and BRISBANE, Australia, Dec. 16,…
Read More » -
The Shyft Group to Merge with Aebi Schmidt Group to Create A Specialty Vehicles Leader
Significant Scale in Attractive North American Market with Strong European Presence Highly Complementary Portfolios Create Opportunities to Better Serve Customers…
Read More » -
KBR Expanding Capabilities for DoD Joint Mission Environment Test Capability Program with $445M Contract Win
HOUSTON, Dec. 16, 2024 /PRNewswire/ — KBR (NYSE: KBR) announced it has been awarded an estimated $445 million cost-plus-fixed-fee contract…
Read More » -
HONEYWELL EXPLORES STRATEGIC ALTERNATIVES FOR UNLOCKING SHAREHOLDER VALUE; CONTINUES REVIEW OF TRANSFORMATIONAL PORTFOLIO ACTIONS
CHARLOTTE, N.C., Dec. 16, 2024 /PRNewswire/ — Honeywell (NASDAQ: HON) announced today that its Board of Directors continues the comprehensive…
Read More » -
A Decade of Progress: Oregon ABLE Transforms Lives with $100 Million Saved
ABLE accounts offer a pathway to financial independence for thousands of Oregonians experiencing disabilities SALEM, Ore., Dec. 16, 2024 /PRNewswire/…
Read More » -
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
Nominated development candidate IDE251, a potential first-in-class KAT6/7 inhibitor IDE251 is targeted to be evaluated in breast and NSCLC with…
Read More » -
Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC
This approval marks the fourth non-small cell lung cancer (NSCLC) indication and the first indication in earlier stages of NSCLC…
Read More »
